menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Treatment Options for Locally-Advanced Squamous Cell Carcinoma of the Head and Neck

    The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology a...

    Available credits: 1.00

    Released:

    Valid until:

    Take Post-Test

    If you’ve already completed the activity.

    • Overview

      The management of metastatic cancers has changed significantly over the last decade with improved understanding of its underlying pathophysiology and signal pathways. However, a significant proportion of patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck has a poor prognosis, in many cases due to late presentation. For those patients, cure is typically not possible; treatment options can prolong life and improve symptoms.  Thus, long-term survival rates in these metastatic settings, while improving, remain unacceptably low.

      Despite advances, the management of patients with metastatic disease continues to present challenges for clinicians. As innovative focused therapeutic options become available and treatment paradigms evolve, the need to discern when and how to incorporate these promising agents into clinicians’ armamentarium presents a great educational need. Moreover, continuing advances in our understanding of cancer pathophysiology, molecular pathways, the optimal and sequential use of targeted therapies in the context of chemotherapy and radiotherapy in the metastatic setting and the therapeutic potential of investigational agents currently being explored for various cancers, suggest educational and clinical practice gaps that must be effectively addressed to further improve outcomes in patients with cancer.

      Given this information, TOPEC Global is pleased to present this module titled “Treatment Options for Locally-Advanced Squamous Cell Carcinoma of the Head and Neck.” This module reviews therapeutic approaches in locally-advanced SCCHN, induction strategies in managing SCCHN, the place of biomarkers and their prognostic significance, and the management of HPV-related SCCHN.

    • Learning Objectives

      At the completion of this module, participants will be better able to:

      1. Describe the therapeutic approaches in locally-advanced SCCHN
      2. Assess and apply induction strategies in patients with SCCHN
      3. Evaluate the potential role of prognostic biomarkers in SCCHN, and the value the may bring to optimizing patient outcomes
      4. Incorporate management strategies for HPV-related SCCHN into their medical practice
    • Target Audience

      This course is designed to meet the Continuing Medical Education needs of oncologists, surgical oncologists and radiotherapists.

    • Commercial Support

      This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.
       
      Original Release Date: 24 September 2015
      Expiration Date: 22 February 2018

    • Accreditation and Credit Designation Statements

      Treatment Options for Locally-Advanced Squamous Cell Carcinoma of the Head and Neck, made available on  www.globaloncologyacademy.org and organized by Siyemi Learning and TOPEC Global, LLC, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

      The course, Treatment Options for Locally-Advanced Squamous Cell Carcinoma of the Head and Neck made available on  www.globaloncologyacademy.org and organized by Siyemi Learning and TOPEC Global, LLC, is awarded 1 European CME credits (ECMEC). Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

      Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited.

      Contact Information
      In case of technical needs, please contact: info@globaloncologyacademy.org

    • Disclosure of Conflicts of Interest

      COURSE DIRECTOR

      Jan B. Vermorken, MD, PhD
      Emeritus Professor of Oncology
      Department of Medical Oncology 
      Antwerp University Hospital 
      Edegem, Belgium
      Financial Relationship Disclosure
      Consultant: Amgen, Genentech, Merck Serono, Shionogi      
      Commercial Interest Speakers Bureau: Merck Serono

      AUTHORS

      Athanassios Argiris, MD, PhD, FACP
      Adjunct Professor
      University of Texas Health Science Center
      San Antonio, TX
      Financial Relationship Disclosure
      Consulting Fees: Bristol-Myers Squibb, Merck Serono, Roche Diagnosis
      Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Roche Diagnostics

      REVIEWER

      Makoto Tahara, MD, PhD
      Department of Head and Neck Medical Oncology
      National Cancer Center Hospital East
      Chiba, Japan
      Financial Relationship Disclosure
      Consultant: Eisai, Merck Serono              
      Commercial Interest Speakers Bureau: Bristol-Myers Squibb, Merck Serono                       
      Contracted Research: Boehringer-Ingelheim, Eisai

    • System Requirements

      Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

    Facebook Comments

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.